Keros Therapeutics (NASDAQ:KROS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a research note released on Monday.

KROS has been the subject of a number of other reports. Zacks Research lowered shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Finally, Leerink Partners dropped their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Stock Down 2.3%

KROS opened at $10.78 on Monday. The stock’s fifty day moving average is $10.72 and its two-hundred day moving average is $11.74. The company has a market capitalization of $213.77 million, a P/E ratio of -2.91 and a beta of 0.99. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities analysts anticipate that Keros Therapeutics will post -5.16 earnings per share for the current year.

Insider Activity

In other Keros Therapeutics news, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares in the company, valued at $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,768 shares of company stock worth $144,979 in the last quarter. 12.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd boosted its position in shares of Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares in the last quarter. California State Teachers Retirement System increased its position in Keros Therapeutics by 72.6% during the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock valued at $29,000 after buying an additional 1,148 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the last quarter. Legal & General Group Plc purchased a new stake in Keros Therapeutics in the second quarter valued at about $90,000. Finally, XTX Topco Ltd acquired a new stake in Keros Therapeutics in the fourth quarter worth about $212,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.